December 10th & 11th, 2026
15th edition
MARSEILLE, FR

Agnostic or pure players in the biotech sector: Who is becoming prominent in the early-stage financing rounds?

Agnostic or pure players in the biotech sector: Who is becoming prominent in the early-stage financing rounds?

The seed investment market is comprised of players with varied degrees of specialisation, from totally agnostic players involved in multiple industries, to pure players focusing on specific therapeutic areas. Do most specialised funds attract the more generalist types in the financing rounds? What is the importance of the amount of seed investment today for cross-industry funds, 100% healthcare-oriented funds, and pure players in the biotech industry, respectively?

Joseph Wagman

Junior Analyst
SOSV

Jacky Vonderscher

CEO
ENYO Pharma

Jeroen Bakker

Senior Associate
Novo Seeds

Jean-Charles Brosse

Partner Healthcare and Life Sciences
Positive Capital

Jan Adams

Managing Director
EMBL Ventures

Jonathan Tobin

Investment Director
Arix Bioscience
Scroll to Top

Before you leave…

Download the official BioFIT 2026 brochure

Discover the conference programme, partnership opportunities, attendee profiles, registration options and everything you need to make the most of BioFIT 2026.